Finall Exam:l NRl 567l NR567l Latestl

Finall Exam:l NRl 567/l NR567l (Latestl

2026/l 2027l Update)l Advancedl Pharmacologyl forl thel AGACNPl Guidel |Q/Al |l Gradel A|l 100%l Correctl (Verifiedl Answers)l -Chamberlain

Q:l Nonergotl Derivativesl (Dopaminel Agonists):l Prototype

Answer:

pramipexole

Q:l pramipexole:l MOA

Answer:

stimulatingl dopamine-2l andl dopamine-3l receptorsl inl thel brain.l Helpsl compensatel forl thel decreasedl dopaminel levelsl inl thel brainl ofl patientsl withl Parkinson's,l leadingl tol improvedl motorl function.

Q:l pramipexole:l Sidel effects

Answer:

Impulsel controll disordersl problemsl withl sleepl GIl effectsl -l nauseal andl constipationl CNSl effectsl -l dizzinessl andl hallucinations Orthostaticl hypotensionl dyskinesiasl canl occurl inl highl doses

• / 4

Q:l pramipexole:l Labsl tol Monitor

Answer:

BMPl -l renall functionl (excretedl here)

Q:l Ergotl Derivatices:l Prototype

Answer:

bromocriptine

Q:l bromocriptine:l MOA

Answer:

stimulatesl dopaminel receptorsl throughl directl activationl therebyl addingl tol thel effectsl ofl dopaminel derivedl froml levodopa

Q:l bromocriptine:l sidel effects

Answer:

GIl effects:l nausea

CNSl effects:l confusion,l nightmares,l agitations,l hallucinations,l andl paranoidl delusions Dyskinesiasl canl occurl posturall hypotensionl rarely,l butl canl causel pulmonaryl infiltrates.

Q:l COMTl Inhibitors:l Prototype

Answer: 2 / 4

entacapone

Q:l entacapone:l MOA

Answer:

Itl enhancesl thel effectl ofl levodopal byl inhibitingl itsl metabolisml inl thel intestinel andl peripherall tissues.l Thisl actionl prolongsl thel half-lifel ofl levodopal andl increasesl itsl availabilityl byl decreasingl thel productionl ofl levodopal metabolitesl thatl competel withl levodopal forl transportl acrossl thel blood-brainl barrier.

Q:l entacapone:l sidel effects

Answer:

Dyskinesial orthostaticl hypotensionl N/V/D/Constipation hallucinations/insomnia behaviorall changesl discolorationl ofl bodyl fluids

Q:l MAO-Bl Inhibitors:l Prototype

Answer:

selegiline

Q:l selegiline:l MOA

Answer:

Thesel medicationsl selectivelyl andl irreversiblyl inhibitl monoaminel oxidase-Bl (MAO-B),l thel enzymel responsiblel forl thel inactivationl ofl dopaminel inl thel brain.l Thisl inhibitionl 3 / 4

increasesl thel availabilityl ofl dopamine,l enhancingl dopaminergicl neurotransmissionl andl alleviatingl symptomsl ofl Parkinson'sl disease.

Q:l selegiline:l sidel effects

Answer:

CNSl -l agitation,l confusion,l dizziness,l orl hallucinations.l orthostaticl hypotension,l atl highl dosesl mayl causel hypertensionl nausea

Q:l Dopaminel Releaser:l Prototype

Answer:

amantadine

Q:l amantadine:l MOA

Answer:

Itl worksl primarilyl byl increasingl dopaminel synthesis,l release,l orl reuptake.

Q:l amantadine:l sidel effects

Answer:

CNSl -l confusion,l lightheadedness,l anxietyl Anticholinergicl effectsl -l dryl mouth,l constipation,l blurredl visionl urinaryl retention Livedol Reticularisl -l mottledl skinl discoloration

Q:l Cholinesterasel Inhibitors:l Prototype

• / 4